A Randomized, Placebo-Controlled, Double-Blind, Single Dose, Phase 1 Study to Explore the PK/PD Relationship of QRL-101 in People Living With ALS

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515021-29-00

Acronym

QRL-101-04

Enrollment

Registered

2024-10-14

Start date

2024-11-11

Completion date

2025-08-22

Last updated

2025-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic lateral sclerosis (ALS)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026